Rolofylline (KW-3902): A new adenosine A1-receptor antagonist for acute congestive heart failure

Sandra Chaparro; Howard C. Dittrich; W. H.Wilson Tang

doi:10.2217/14796678.4.2.117

Rolofylline (KW-3902): A new adenosine A1-receptor antagonist for acute congestive heart failure

Sandra Chaparro, Howard C. Dittrich, W. H.Wilson Tang

Medicine

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

Original language	English (US)
Pages (from-to)	117-123
Number of pages	7
Journal	Future Cardiology
Volume	4
Issue number	2
DOIs	https://doi.org/10.2217/14796678.4.2.117
State	Published - Mar 1 2008

Fingerprint

Keywords

Adenosine A1 receptor antagonist
Cardiorenal syndrome
Heart failure
KW-3902
Natriuresis
Renal function
Rolofylline

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Molecular Medicine

Cite this

Chaparro, S., Dittrich, H. C., & Tang, W. H. W. (2008). Rolofylline (KW-3902): A new adenosine A1-receptor antagonist for acute congestive heart failure. Future Cardiology, 4(2), 117-123. https://doi.org/10.2217/14796678.4.2.117

@article{c258648535af4dc6a86a8c420dba5aaa,

title = "Rolofylline (KW-3902): A new adenosine A1-receptor antagonist for acute congestive heart failure",

abstract = "Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.",

keywords = "Adenosine A1 receptor antagonist, Cardiorenal syndrome, Heart failure, KW-3902, Natriuresis, Renal function, Rolofylline",

author = "Sandra Chaparro and Dittrich, {Howard C.} and Tang, {W. H.Wilson}",

year = "2008",

month = mar

day = "1",

doi = "10.2217/14796678.4.2.117",

language = "English (US)",

volume = "4",

pages = "117--123",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Rolofylline (KW-3902)

T2 - A new adenosine A1-receptor antagonist for acute congestive heart failure

AU - Chaparro, Sandra

AU - Dittrich, Howard C.

AU - Tang, W. H.Wilson

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

AB - Rolofylline (KW-3902 or MK-7418) is an adenosine A1-receptor antagonist that exerts its effect by blocking adenosine-mediated constriction of the afferent glomerular arteriole. By blocking A1 receptors, rolofylline increases the glomerular blood flow and filtration and inhibits sodium reabsorption in the proximal tubule, thereby enhancing natriuresis and diuresis. Early phase clinical research data provided the proof-of-concept of an incremental effect beyond standard diuretic therapy. A large Phase III program is currently ongoing for the intravenous formulation of rolofylline in the treatment of acute heart failure.

KW - Adenosine A1 receptor antagonist

KW - Cardiorenal syndrome

KW - Heart failure

KW - KW-3902

KW - Natriuresis

KW - Renal function

KW - Rolofylline

UR - http://www.scopus.com/inward/record.url?scp=40649115008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649115008&partnerID=8YFLogxK

U2 - 10.2217/14796678.4.2.117

DO - 10.2217/14796678.4.2.117

M3 - Article

C2 - 19804290

AN - SCOPUS:40649115008

VL - 4

SP - 117

EP - 123

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -

Access to Document

10.2217/14796678.4.2.117